Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BeOne Medicines Ltd. Class A (688235.SS)
Basel, CH
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | +5.09% | +9.77% | -5.21% | -8.73% | -0.23% | +20.98% | +80.52% | +66.47% | +66.47% | +66.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+44.1% ★ Q1'26: +36.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+103.3% ★ Q1'26: +1,215.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.4% Q1'26: +10.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.4% ★ Q1'26: +16.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+17.9% ★ Q1'26: +44.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,300.8% Q1'26: +1,253.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.30× ★ Q1'26: 1.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 32 Rev. Ana. 1 EPS Ana. |
Dec 2027 34 Rev. Ana. 1 EPS Ana. |
Dec 2028 26 Rev. Ana. 1 EPS Ana. |
Dec 2029 31 Rev. Ana. 1 EPS Ana. |
Dec 2030 17 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.82M
est: 7.63M (+15.6%)
|
1.07M
est: 4.52M (-76.3%)
|
238.39M
est: 244.58M (-2.5%)
|
198.22M
est: 198.13M (+0.0%)
|
428.21M
est: 440.01M (-2.7%)
|
308.87M
est: 331.34M (-6.8%)
|
1.18B
est: 1.20B (-1.9%)
|
1.42B
est: 1.43B (-0.7%)
|
2.46B
est: 2.47B (-0.3%)
|
3.81B
est: 3.71B (+2.7%)
|
5.49B
est: 5.32B (+3.2%)
|
6.42B
6.17B – 6.81B
+20.6% YoY
|
7.42B
6.86B – 8.07B
+15.6% YoY
|
8.34B
7.85B – 8.97B
+12.4% YoY
|
9.25B
8.70B – 9.94B
+10.9% YoY
|
10.35B
9.74B – 11.13B
+12.0% YoY
|
| EBITDA |
-55.20M
est: -5.43M (-915.7%)
|
-115.15M
est: -3.22M (-3,478.0%)
|
-93.70M
est: -174.28M (+46.2%)
|
-695.38M
est: -141.18M (-392.5%)
|
-941.27M
est: -313.54M (-200.2%)
|
-1.63B
est: -236.10M (-588.6%)
|
-1.39B
est: -854.85M (-63.0%)
|
-1.73B
est: -1.02B (-69.9%)
|
-1.12B
est: -1.76B (+36.0%)
|
-401.98M
est: -1.82B (+77.9%)
|
605.11M
est: -2.61B (+123.2%)
|
-3.15B
-3.34B – -3.02B
-20.6% YoY
|
-3.64B
-3.96B – -3.36B
-15.6% YoY
|
-4.09B
-4.40B – -3.85B
-12.4% YoY
|
-4.54B
-4.88B – -4.27B
-10.9% YoY
|
-5.08B
-5.46B – -4.78B
-12.0% YoY
|
| EBIT |
-56.75M
est: -5.55M (-921.8%)
|
-117.06M
est: -3.29M (-3,459.4%)
|
-98.46M
est: -178.09M (+44.7%)
|
-705.77M
est: -144.27M (-389.2%)
|
-959.89M
est: -320.40M (-199.6%)
|
-1.66B
est: -241.27M (-587.1%)
|
-1.44B
est: -873.56M (-64.7%)
|
-1.79B
est: -1.04B (-72.3%)
|
-1.21B
est: -1.80B (+32.7%)
|
-569.01M
est: -1.90B (+70.0%)
|
459.50M
est: -2.72B (+116.9%)
|
-3.28B
-3.48B – -3.15B
-20.6% YoY
|
-3.79B
-4.13B – -3.51B
-15.6% YoY
|
-4.27B
-4.59B – -4.02B
-12.4% YoY
|
-4.73B
-5.09B – -4.45B
-10.9% YoY
|
-5.29B
-5.69B – -4.98B
-12.0% YoY
|
| Net Income |
-57.10M
est: -20.63M (-176.8%)
|
-119.22M
est: -31.93M (-273.4%)
|
-93.11M
est: -12.45M (-648.0%)
|
-673.77M
est: -89.46M (-653.2%)
|
-948.63M
est: -111.30M (-752.3%)
|
-1.62B
est: -150.94M (-976.6%)
|
-1.46B
est: -106.41M (-1,270.0%)
|
-2.00B
est: -160.27M (-1,150.3%)
|
-881.71M
est: -72.71M (-1,112.6%)
|
-644.79M
est: -991.91M (+35.0%)
|
294.87M
est: 570.38M (-48.3%)
|
1.18B
1.09B – 1.29B
+106.7% YoY
|
1.75B
1.62B – 1.93B
+48.7% YoY
|
2.41B
2.23B – 2.65B
+37.4% YoY
|
2.72B
2.52B – 2.99B
+13.0% YoY
|
3.42B
3.16B – 3.76B
+25.7% YoY
|
| SGA |
7.31M
est: 7.29M (+0.2%)
|
20.10M
est: 4.32M (+365.2%)
|
62.60M
est: 233.93M (-73.2%)
|
195.39M
est: 189.50M (+3.1%)
|
388.25M
est: 420.85M (-7.7%)
|
600.18M
est: 316.91M (+89.4%)
|
990.12M
est: 1.15B (-13.7%)
|
1.28B
est: 1.36B (-6.3%)
|
1.51B
est: 2.36B (-36.0%)
|
1.83B
est: 2.39B (-23.3%)
|
2.09B
est: 3.43B (-39.0%)
|
4.13B
3.97B – 4.39B
+20.6% YoY
|
4.78B
4.42B – 5.20B
+15.6% YoY
|
5.37B
5.06B – 5.78B
+12.4% YoY
|
5.95B
5.60B – 6.40B
+10.9% YoY
|
6.67B
6.28B – 7.17B
+12.0% YoY
|
| EPS |
-6.71
est: -0.20 (-3,325.2%)
|
-3.84
est: -0.30 (-1,166.3%)
|
-2.23
est: -0.12 (-1,786.3%)
|
-12.15
est: -0.85 (-1,330.0%)
|
-15.80
est: -1.06 (-1,394.6%)
|
-19.47
est: -1.43 (-1,258.1%)
|
-15.71
est: -1.01 (-1,454.4%)
|
-19.43
est: -1.52 (-1,176.5%)
|
-8.45
est: -0.69 (-1,123.6%)
|
-6.12
est: -0.67 (-810.0%)
|
0.21
est: 0.39 (-45.7%)
|
0.80
0.74 – 0.88
+106.7% YoY
|
1.19
1.10 – 1.31
+48.7% YoY
|
1.63
1.51 – 1.79
+37.4% YoY
|
1.85
1.71 – 2.03
+13.0% YoY
|
2.32
2.14 – 2.55
+25.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Neuberger Berman China Equity ETF NBCE | 0.70% | 129.2K | 5.01% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.29% | 106.0K | 0.65% |
| 3 | Kodex FTSE China A50 169950.KS | 0.15% | 23.7K | 0.12% |
| 4 | VanEck - FTSE China A50 ETF CETF.AX | 0.15% | 38.4K | 0.60% |
| 5 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.09% | 14.7K | 0.65% |
| 6 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.08% | 57.4K | 0.55% |
| 7 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.05% | 246.3K | 0.32% |
| 8 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.03% | 1.37M | 0.15% |
| 9 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.03% | 1.36M | 0.15% |
| 10 | Goldman Sachs MarketBeta Total International Equity ETF GXUS | 0.02% | 103.2K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | 29M | — |
| John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | 20M | male |
| Wang Lai | President and Global Head of Research & Development | 9M | male |
| Aaron Rosenberg | Chief Financial Officer | 9M | male |
| Chan Lee | General Counsel, Senior VP & Corporate Secretary | 9M | male |
| Liza Heapes | Head of Investor Relations | — | female |
| Marcello Damiani | Chief Technology Officer | — | male |
| Graham Hardiman | Global Head of Human Resources | — | male |
| Titus Ball | Vice President & Chief Accounting Officer | — | male |
| Eleanor Duff | Senior Vice President & Head of Corporate Communications | — | female |
| Mark Lanasa | Senior Vice President & Chief Medical Officer for Solid Tumors | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688235.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
